Oviva, which provides a tech-based approach for Type 2 diabetes treatment in Europe, raises $21M Series B led by MTIP, bringing its total raised to $34M
Context & Ripple Effects
Oviva's $21M Series B, led by MTIP, lands in a funding lane that has been widening since Livongo's $105M Series E at a $800M+ valuation in 2018: venture capital treating diabetes management as a software business rather than a hardware one. Oviva's version is app-delivered diet and lifestyle coaching for Type 2 patients in Europe, where no homegrown equivalent of the US leaders had yet raised at scale.
The US side of the market is moving faster on dollars — Virta's $65M raise at a ~$1.1B valuation in late 2019 was followed by a $133M Series E valuing it at $2B — which frames MTIP's bet as an early European answer to a category the Americans have already priced.
First-order effects
- Oviva gains the capital to scale its app-based Type 2 diabetes treatment across European markets, moving from a $13M to a $34M funding base under a specialist health-tech lead investor in MTIP.
- European health systems and insurers evaluating digital diabetes care now have a funded local option alongside the US-backed telehealth models from Virta and Livongo.
Second-order effects
- Virta's rapid valuation climb to $2B sets a benchmark that pressures later Oviva rounds — and indeed Oviva went on to raise an $80M Series C led by Sofina and Temasek — while forcing European insurers to decide whether app-based dietary coaching merits reimbursement parity with device-heavy programs.
- Competing approaches in the same condition, like Beta Bionics' FDA-cleared automated insulin dosing software, sharpen the market split between software that manages diabetes through behavior change and software that manages it through dosing hardware.
Third-order effects
- If the funding cadence holds, diabetes care in Europe consolidates around software-first providers whose clinical outcomes data becomes the basis for insurer reimbursement, with capital favoring dietary-remission models over connected-device platforms.
- The US-Europe gap in digital diabetes valuations points toward cross-border expansion by the category leaders, making Oviva's European foothold a potential acquisition target or a regional counterweight depending on how its Series C deployment goes.
The trend: Venture capital is re-pricing diabetes care as a software category, with escalating rounds — Livongo in 2018, Virta through 2021, Oviva across 2020-2021 — shifting treatment from connected devices toward app-delivered behavioral therapy.